United States-based Frazier Healthcare Partners has introduced Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections, it was reported yesterday.
Recida's lead program, RC-01, is a novel, IND-stage LpxC inhibitor intended for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialisation rights to RC-01 from FUJIFILM Toyama Chemical Co Ltd for all territories outside Japan. The company intends to submit an Investigational New Drug (IND) application for the product to the United States Food and Drug Administration (FDA) in the first quarter of 2019.
The product inhibits bacterial LpxC, a key enzyme in Lipid A biosynthesis. It exhibits a broad spectrum of rapid, in vitro and in vivo bactericidal activity against major clinically relevant pathogens such as the Enterobacteriaceae and Pseudomonas aeruginosa.
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a Boston University global partnership funded by the US has awarded Recida up to USD4.4m to help fund the preparation of an IND application, a Phase 1 trial to be completed in 2019 and drug product manufacturing to support subsequent Phase 2 studies.
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder